![](/img/cover-not-exists.png)
An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
Horgan, A. M., Bradbury, P. A., Amir, E., Ng, R., Douillard, J. Y., Kim, E. S., Shepherd, F. A., Leighl, N. B.Volume:
22
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdq682
Date:
August, 2011
File:
PDF, 106 KB
english, 2011